Axsome Therapeutics AXSM Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's inventories?
- Axsome Therapeutics (AXSM) reported inventories of $31.52M in Q1 2026.
- How has Axsome Therapeutics's inventories changed year-over-year?
- Axsome Therapeutics's inventories increased by 93.1% year-over-year, from $16.32M to $31.52M.
- What is the long-term trend for Axsome Therapeutics's inventories?
- Over 3 years (2022 to 2025), Axsome Therapeutics's inventories has grown at a 86.3% compound annual growth rate (CAGR), from $4.32M to $27.94M.
- What does inventories mean?
- The value of all goods and materials the company currently has in stock.
- How do you interpret inventories?
- Rising inventory levels may indicate anticipated sales growth or, conversely, potential obsolescence or overproduction.
- How does inventories compare across companies?
- Inventory levels scale significantly once a company transitions from clinical development to commercial product distribution.